153 related articles for article (PubMed ID: 34878138)
21. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
Linde HJ; Lehn N
J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
[TBL] [Abstract][Full Text] [Related]
22. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
24. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
[TBL] [Abstract][Full Text] [Related]
25. Impact of low-level fluoroquinolone resistance genes qnrA1, qnrB19 and qnrS1 on ciprofloxacin treatment of isogenic Escherichia coli strains in a murine urinary tract infection model.
Jakobsen L; Cattoir V; Jensen KS; Hammerum AM; Nordmann P; Frimodt-Møller N
J Antimicrob Chemother; 2012 Oct; 67(10):2438-44. PubMed ID: 22685162
[TBL] [Abstract][Full Text] [Related]
26. In vitro selection of resistance to pradofloxacin and ciprofloxacin in canine uropathogenic Escherichia coli isolates.
Liu X; Lazzaroni C; Aly SA; Thungrat K; Boothe DM
Vet Microbiol; 2014 Dec; 174(3-4):514-522. PubMed ID: 25465666
[TBL] [Abstract][Full Text] [Related]
27. Role of low-level quinolone resistance in generating tolerance in Escherichia coli under therapeutic concentrations of ciprofloxacin.
Ortiz-Padilla M; Diaz-Diaz S; Machuca J; Tejada-Gonzalez A; Recacha E; Docobo-Pérez F; Pascual A; Rodríguez-Martínez JM
J Antimicrob Chemother; 2020 Aug; 75(8):2124-2132. PubMed ID: 32427318
[TBL] [Abstract][Full Text] [Related]
28. Mutant prevention concentration of orbifloxacin: comparison between Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus pseudintermedius of canine origin.
Shimizu T; Harada K; Kataoka Y
Acta Vet Scand; 2013 May; 55(1):37. PubMed ID: 23634902
[TBL] [Abstract][Full Text] [Related]
29. Study of the contribution of active defense mechanisms to ciprofloxacin tolerance in Escherichia coli growing at different rates.
Smirnova GV; Tyulenev AV; Muzyka NG; Oktyabrsky ON
Antonie Van Leeuwenhoek; 2022 Feb; 115(2):233-251. PubMed ID: 35022927
[TBL] [Abstract][Full Text] [Related]
30. Characterization of the Pseudomonas aeruginosa recA analog and its protein product: rec-102 is a mutant allele of the P. aeruginosa PAO recA gene.
Kokjohn TA; Miller RV
J Bacteriol; 1987 Apr; 169(4):1499-508. PubMed ID: 3031014
[TBL] [Abstract][Full Text] [Related]
31. Mutations That Enhance the Ciprofloxacin Resistance of Escherichia coli with qnrA1.
Vinué L; Corcoran MA; Hooper DC; Jacoby GA
Antimicrob Agents Chemother; 2015 Dec; 60(3):1537-45. PubMed ID: 26711751
[TBL] [Abstract][Full Text] [Related]
32. Oxygenated monoterpenes citral and carvacrol cause oxidative damage in Escherichia coli without the involvement of tricarboxylic acid cycle and Fenton reaction.
Chueca B; Pagán R; García-Gonzalo D
Int J Food Microbiol; 2014 Oct; 189():126-31. PubMed ID: 25146464
[TBL] [Abstract][Full Text] [Related]
33. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
[TBL] [Abstract][Full Text] [Related]
34. Chromosomal lesion suppression and removal in Escherichia coli via linear DNA degradation.
Miranda A; Kuzminov A
Genetics; 2003 Apr; 163(4):1255-71. PubMed ID: 12702673
[TBL] [Abstract][Full Text] [Related]
35. [Role of double strand DNA break repair for quinolone sensitivity in Escherichia coli: therapeutic implications].
González-Soltero R; García-Cañas A; Mohedano RB; Mendoza-Chamizo B; Botello E
Rev Esp Quimioter; 2015 Jun; 28(3):139-44. PubMed ID: 26032998
[TBL] [Abstract][Full Text] [Related]
36. [Expression of gene recA of Deinococcus radiodurans in Escherichia coli cells].
Verbenko VN; Kuznetsova LV; Krup'ian EP; Shalguev VI
Genetika; 2009 Oct; 45(10):1353-60. PubMed ID: 19947546
[TBL] [Abstract][Full Text] [Related]
37. In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations.
Drago L; Nicola L; Mattina R; De Vecchi E
BMC Microbiol; 2010 Apr; 10():119. PubMed ID: 20409341
[TBL] [Abstract][Full Text] [Related]
38. Mutant prevention concentrations of ciprofloxacin against urinary isolates of Escherichia coli and Klebsiella pneumoniae.
Daoud Z; Sokhn ES; Azar E; Masri K; Doron S
J Infect Dev Ctries; 2014 Feb; 8(2):154-9. PubMed ID: 24518624
[TBL] [Abstract][Full Text] [Related]
39. An evaluation of the potential of the multiple antibiotic resistance operon (mar) and the multidrug efflux pump acrAB to moderate resistance towards ciprofloxacin in Escherichia coli biofilms.
Maira-Litrán T; Allison DG; Gilbert P
J Antimicrob Chemother; 2000 Jun; 45(6):789-95. PubMed ID: 10837431
[TBL] [Abstract][Full Text] [Related]
40. Inhibitors of RecA activity discovered by high-throughput screening: cell-permeable small molecules attenuate the SOS response in Escherichia coli.
Wigle TJ; Sexton JZ; Gromova AV; Hadimani MB; Hughes MA; Smith GR; Yeh LA; Singleton SF
J Biomol Screen; 2009 Oct; 14(9):1092-101. PubMed ID: 19675313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
